These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35174666)

  • 41. Mechanistic Investigations Support Liver Safety of Ubrogepant.
    Smith B; Rowe J; Watkins PB; Ashina M; Woodhead JL; Sistare FD; Goadsby PJ
    Toxicol Sci; 2020 Sep; 177(1):84-93. PubMed ID: 32579200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. To Probe the Binding Interactions between Two FDA Approved Migraine Drugs (Ubrogepant and Rimegepant) and Calcitonin-Gene Related Peptide Receptor (CGRPR) Using Molecular Dynamics Simulations.
    Leung L; Liao S; Wu C
    ACS Chem Neurosci; 2021 Jul; 12(14):2629-2642. PubMed ID: 34184869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment.
    Li CC; Voss T; Kowalski K; Yang B; Kleijn HJ; Jones CJ; Bosch R; Michelson D; DeAngelis M; Xu Y; Xie I; Kothare PA
    Clin Transl Sci; 2020 May; 13(3):482-490. PubMed ID: 31758661
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor.
    Moore E; Fraley ME; Bell IM; Burgey CS; White RB; Li CC; Regan CP; Danziger A; Stranieri Michener M; Hostetler E; Banerjee P; Salvatore C
    J Pharmacol Exp Ther; 2020 Jan; ():. PubMed ID: 31992609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling.
    Li CC; Dockendorf M; Kowalski K; Yang B; Xu Y; Xie I; Kleijn HJ; Bosch R; Jones C; Thornton B; Marcantonio EE; Voss T; Bateman KP; Kothare PA
    J Clin Pharmacol; 2018 Mar; 58(3):294-303. PubMed ID: 29136283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ubrogepant in the Acute Management of Migraine: A Narrative Review.
    Chiang CC; VanderPluym JH
    J Pain Res; 2021; 14():1185-1192. PubMed ID: 33948091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment.
    Taylor L; Crockett J; Tayo B; Morrison G
    J Clin Pharmacol; 2019 Aug; 59(8):1110-1119. PubMed ID: 30921490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
    Kusawake T; Kowalski D; Takada A; Kato K; Katashima M; Keirns JJ; Lewand M; Lasseter KC; Marbury TC; Preston RA
    Adv Ther; 2017 Dec; 34(12):2612-2624. PubMed ID: 29134428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
    Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
    Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist.
    Joyner KR; Morgan KW
    Ann Pharmacother; 2021 Jun; 55(6):745-759. PubMed ID: 32993366
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials.
    Bentz Damholt B; Dombernowsky SL; Dahl Bendtsen M; Bisgaard C; Højby Rasmussen M
    Clin Pharmacokinet; 2021 Aug; 60(8):1015-1027. PubMed ID: 33754315
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
    Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
    Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.
    Perera V; Abelian G; Li D; Wang Z; Zhang L; Lubin S; Chen W; Bello A; Murthy B
    Clin Pharmacokinet; 2022 Jun; 61(6):857-867. PubMed ID: 35262846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
    Saif MW; Rosen L; Rudek MA; Sun W; Shepard DR; Becerra C; Yamashita F; Bebeau P; Winkler R
    Br J Clin Pharmacol; 2019 Jun; 85(6):1239-1246. PubMed ID: 30628113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.
    Jensen L; Kupcova V; Arold G; Pettersson J; Hjerpsted JB
    Diabetes Obes Metab; 2018 Apr; 20(4):998-1005. PubMed ID: 29205786
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.